South Korea Diabetes Drugs Market Forecast: AI Monitoring, Smart Care & Forecast to 2034

Rising diabetes prevalence, increasing adoption of advanced technologies and telemedicine, and the expansion of hospitals, clinics, and other healthcare facilities are driving demand for pharmaceutical interventions in South Korea. According to IMARC Group's latest data, the South Korea diabetes drugs market size was valued at USD 1.90 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 4.90 Billion by 2034. Hospital pharmacies currently dominate the market, holding a significant share in 2025.

The south korea diabetes drugs market is undergoing rapid transformation driven by a rising type 2 diabetes burden linked to sedentary lifestyles, dietary shifts, and an aging population. Physicians are increasingly prescribing combination medications targeting multiple facets of diabetes management simultaneously, including glucose control, insulin sensitivity, and weight management. Advanced drug classes such as SGLT-2 inhibitors and GLP-1 receptor agonists are gaining considerable traction due to their cardiovascular and renal protective benefits alongside glycemic control. Integration of continuous glucose monitors, connected insulin pens, and mobile health applications has further reshaped patient management pathways. Government-backed universal healthcare coverage and chronic disease management frameworks continue to expand the addressable treatment population across urban and rural segments alike.

Get a Sample Report for Actionable Market Insights

South Korea Diabetes Drugs Market Growth Drivers:

Rising Prevalence of Diabetes

South Korea's shift toward sedentary urban lifestyles and calorie-dense diets has significantly elevated the country's type 2 diabetes burden. Approximately 1 in 8 South Korean adults is estimated to be living with diabetes, with a substantial portion remaining undiagnosed. The aging population compounds this challenge, as older demographics carry higher susceptibility to insulin resistance and metabolic disorders. Prediabetes rates are accelerating the pipeline of future patients entering pharmaceutical treatment programs, creating a durable, high-volume prescription base. The south korea diabetes drugs market, currently valued at USD 1.90 Billion, benefits directly from this expanding patient population, with lifestyle-linked complications such as cardiovascular disease and chronic kidney disease further amplifying demand for multi-target drug regimens.

Adoption of Advanced Technologies and Telemedicine

The deep integration of digital health tools into patient care pathways is a defining feature of the south korea diabetes drugs market. Telemedicine platforms allow endocrinologists to remotely monitor glucose trends, adjust dosages in real time, and reduce the need for frequent hospital visits, improving medication adherence and accelerating transitions to advanced pharmacological regimens. South Korea's advanced broadband infrastructure and high smartphone penetration make it a natural environment for digital pharmacy adoption, expanding access beyond metropolitan centers. Online pharmacies are gaining ground rapidly, supported by telemedicine integration and digital health policy reforms. This technological momentum, within a market currently worth USD 1.90 Billion, is creating new commercial avenues for pharmaceutical companies introducing innovative diabetes drug solutions.

Expansion of Healthcare Infrastructure

Governing authorities in South Korea are focusing on improving healthcare accessibility and affordability through structured policy frameworks. The National Health Insurance Service provides broad coverage for diabetes medications, including newer classes such as SGLT-2 inhibitors and GLP-1 receptor agonists, making advanced therapies financially accessible across income segments. The government's emphasis on preventive healthcare and early diagnosis under its chronic disease management framework has expanded the pool of patients entering pharmaceutical treatment earlier in disease progression. Hospital pharmacies serve as the dominant dispensing channel, particularly for complex regimens requiring clinical supervision. These policy and infrastructure investments underpin the south korea diabetes drugs market's trajectory toward USD 4.90 Billion, reinforcing sustained pharmaceutical demand across all distribution channels.

South Korea Diabetes Drugs Market Trends:

Shift Toward Combination Drug Regimens

Physicians are increasingly prescribing combination medications that address multiple facets of diabetes management within a single formulation, including glucose control, insulin sensitivity, and weight regulation. Pharmaceutical companies are actively developing fixed-dose combination tablets to improve patient compliance and reduce the burden of managing multiple prescriptions. Domestic firms such as Dong-A ST and Boryung Pharmaceutical are investing in combination oral formulations tailored to Korean patient profiles, while global players focus on injectable combination protocols. This trend is fundamentally reshaping prescription behaviors and driving R&D investment, reinforcing the south korea diabetes drugs market's strong growth momentum within its current USD 1.90 Billion valuation.

Growth of GLP-1 Receptor Agonists and SGLT-2 Inhibitors

Non-insulin injectable drugs, especially GLP-1 receptor agonists, are among the fastest-growing sub-segments of the south korea diabetes drugs market, driven by their dual benefits of blood sugar regulation and weight management. SGLT-2 inhibitors are gaining equally strong traction due to their established cardiovascular and renal protective properties, which align with South Korea's rising rates of diabetes-associated comorbidities. The Korean Diabetes Association regularly updates national treatment guidelines, directly influencing prescription patterns and creating structured, sustained demand for these advanced drug classes. Global majors including Novo Nordisk, AstraZeneca, Eli Lilly, and Boehringer Ingelheim are prioritizing this segment within a market demonstrating highly favorable demand dynamics.

Biosimilar Insulin Expansion

Biosimilar insulins are emerging as a strategically important sub-segment within the south korea diabetes drugs market, enabling cost-sensitive patient segments to access insulin therapy at significantly lower price points without compromising clinical efficacy. Domestic pharmaceutical manufacturers are leveraging South Korea's strong regulatory infrastructure and biomanufacturing capabilities to develop and commercialize biosimilar insulin products. This expansion is broadening the insulins category beyond basal and bolus originator products, introducing competitive pricing dynamics that improve treatment accessibility. The Ministry of Food and Drug Safety has maintained a structured biosimilar approval pathway that supports this momentum, contributing to the market's overall upward trajectory toward its projected USD 4.90 Billion valuation.

Recent News and Developments in South Korea Diabetes Drugs Market

March 2025: Novo Nordisk announced expanded distribution of its GLP-1 receptor agonist portfolio in South Korea, targeting tier-2 cities through partnerships with regional hospital networks to capture demand beyond Seoul's metropolitan area and reach a broader patient population.

January 2025: AstraZeneca Korea secured an expanded National Health Insurance Service reimbursement listing for its SGLT-2 inhibitor Farxiga, enabling broader prescription coverage for diabetic patients with concurrent chronic kidney disease and significantly widening the addressable treatment population.

October 2024: Dong-A ST received regulatory approval from the Ministry of Food and Drug Safety for a new fixed-dose combination tablet targeting type 2 patients, combining a DPP-4 inhibitor with metformin in a once-daily formulation designed to improve patient compliance and reduce daily pill burden.

July 2024: The Korean government announced an expansion of its chronic disease management pilot program, integrating digital glucose monitoring data into primary care workflows and unlocking new prescription pathways for pharmaceutical providers operating in the digital health ecosystem.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.